We are forever getting loads of rubbish dumped in our Lane. I don’t know why only that people come off the Thanet Way and down our lane to Whitstable.
The Council have only just taken a pile of broken wood drawers and rubbish and now we have this pile of builders rubble. ray said it looks like a garage or a barn floor. It really is lazy and now the council have to pay for some heavy lifting gear.
Our lovely countryside is so spoilt by these stupid people. Of course me on my Asbestos trail had the first thought of asbestos but there isn’t any that we can see.
I had a lovely email from St Barts mainly because I’m a patient Research Rep so I was sent all the link’s to the Report Of the The Adam Trial that Peter is describing here in the Video.
Arginine, a semi-essential amino acid in humans, is critical for the growth of human cancers, particularly those marked by de novo chemoresistance and a poor clinical outcome. In addition to protein synthesis, arginine is involved in diverse aspects of tumour metabolism, including the synthesis of nitric oxide, polyamines, nucleotides, proline and glutamate.
However, several tumours are unable to produce arginine, due to variable loss of the enzyme argininosuccinate synthetase ASS1, which is necesary for L-arginine synthesisis. Including: hepatocellular carcinoma, malignant melanoma, malignant pleural mesothelioma, prostate and renal cancer.
Our lab is exploring why ASS1 is aberrantly expressed in human cancers. We have identified methylation-dependent silencing of ASS1 in several tumours, including mesothelioma, ovarian cancer and lymphoma, that are sensitive to arginine deprivation. We are now testing whether the ASS1-deficiency of mesothelioma may be exploited using the arginine-lowering agent, pegylated arginine deiminase (ADI-PEG20). Several phase I/II clinical trials of pegylated arginine deiminase have shown encouraging evidence of clinical benefit and low toxicity in patients with ASS1-negative tumours.
Preclinical work in the area of arginine degradation is ongoing in several cancers with our national and international collaborators and industry. We are studying the regulation and modulation of ASS1 expression and the role of the proinflammatory microenvironment in arginine auxotrophic cancers, with the long-term aim of developing novel therapeutic strategies incorporating arginine deprivation and ASS1 loss into routine oncological practice.
We continue to study the links between inflammation and metabolism to discover novel therapeutic targets in oncology.
The ADAM trial has been published online this month in The Journal of the American Medical Association – Oncology and is downloadable via the link:-http://oncology.jamanetwork.com/article.aspx?articleid=2546657
There’s also an informative accompanying commentary in the journal:-
Peter said –Thanks again for taking part (as one of the screened patients)! This is because I was trying to get onto the Adams Trial but I didn’t have Argine in my Tumour. I remember the day I went to Hommerton Hospital so well for my Bi-Op as it was the day after the Riots in Brixton and Hommenton.
I was very worried but the fighting had stopped and we got through safely.
Ps The articles are downloadable by signing in for a guest account
Until recently, cisplatin and pemetrexed disodium doublet chemotherapy was the only anticancer treatment with a median overall survival benefit in malignant …
Research from JAMA Oncology — Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural